Kynexis

Executive Summary

Kynexis is a clinical-stage biotechnology company developing precision medicines for neurological and psychiatric disorders, with a focus on addressing cognitive dysfunction. Founded in 2019 and headquartered in San Diego, the company has raised $57 million to advance its lead program targeting a specific biological mechanism implicated in cognitive impairment. By tailoring therapeutics to well-defined patient subpopulations with high unmet need, Kynexis aims to improve outcomes in conditions such as schizophrenia, Alzheimer's disease, and other neuropsychiatric disorders. The company's approach leverages biomarker-driven patient selection to enhance the probability of success in clinical trials and ultimately deliver more effective treatments. Kynexis is currently conducting Phase 2 clinical trials for its lead candidate, with top-line data expected in the near term. The company's pipeline also includes earlier-stage programs targeting additional neurological indications. As a private company, Kynexis may seek further funding or partnership opportunities to support its development efforts and expand its pipeline. With a focused strategy and a precision medicine approach, Kynexis is positioned to address significant gaps in the treatment of cognitive dysfunction across multiple disorders.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 Top-Line Data Readout55% success
• TBDPotential Strategic Partnership or Licensing Deal40% success
• Q4 2026Regulatory Guidance for Phase 3 Program50% success